Actively Recruiting
Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
Led by Hunan Cancer Hospital · Updated on 2022-04-13
1000
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The phenotype of circulating tumor cells (CTCs) is supposed to be significant indicator that is correlated the prognosis of breast cancer patients who have completed neoadjuvant chemotherapy, primary tumor surgery with/without adjuvant chemotherapy. The aim of this observational study is to assess the efficacy of CTCs surveillance in predicting the prognosis of breast cancer patients.
CONDITIONS
Official Title
Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age is more than 18 years old
- Pathology confirmed malignant breast tumor
- No clinical diagnosis of other malignancies, unstable complications, or uncontrolled infection
- Life expectancy is greater than 6 months
- Main organ function is normal
- Volunteered to participate, signed informed consent, and can comply with follow-up
You will not qualify if you...
- History of other malignant tumors
- Uncontrolled bacterial, viral, or fungal infections
- Physical or mental disorders
- Without or limited civil capacity
- Infected with human immunodeficiency virus (HIV)
- Investigator considers participation inappropriate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hunan Cancer Hospital
Changsha, Hunan, China, 410006
Actively Recruiting
Research Team
Q
Quchang Ouyang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here